We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

QIAGEN Launches First FDA-approved Companion Diagnostic Using FGFR Alterations to Help Guide the Treatment of Metastatic Urothelial Cancer

Product News   Apr 15, 2019

 
QIAGEN Launches First FDA-approved Companion Diagnostic Using FGFR Alterations to Help Guide the Treatment of Metastatic Urothelial Cancer

Image credit: QIAGEN

FURTHER INFORMATION
 
 
 

Related Product News

Maximise PCR Success by Minimising Potential DNA

Product News

Syngene has announced it is now supplying the AirClean® AC600 Series of PCR Workstations, which use UV irradiation to minimize the risk of airborne DNA contamination.

READ MORE

Horizon Partners with the Human Protein Atlas

Product News

Horizon has entered into a partnership with The Human Protein Atlas, providing CRISPR-edited knockout cell models.

READ MORE

Engineering Recombinant Antibodies into New Formats

Product News

Absolute Antibody has announced a partnership with the Recombinant Antibody Network (RAN), engineering select recombinant antibodies into new formats and making thema available to a wider scientific audience.

READ MORE

Like what you just read? You can find similar content on the communities below.

Cancer Research Cell Science Drug Discovery Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE